Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
10 déc. 2024 18h26 HE
|
Myriad Genetics, Inc.
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10 déc. 2024 16h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
10 déc. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
09 déc. 2024 16h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
09 déc. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
NeuroAge Therapeutics: Revolutionary Brain Health Test Predicts Dementia Risk 30 Years in Advance
25 nov. 2024 21h01 HE
|
NeuroAge Therapeutics
NeuroAge Therapeutics launches the NeuroAge Test, a cutting-edge tool predicting dementia risk 30 years early to optimize brain health
Baylor Genetics Wins BioTech Breakthrough Award
19 nov. 2024 10h00 HE
|
Baylor Genetics
Baylor Genetics announced its selection as the 2024 winner of the “Overall Genomics Solution of the Year" from BioTech Breakthrough.
Saudi Arabia Genetic Testing Market and 10 Year Forecast Report 2019-2029, Featuring Anwa Medical Labs, NoorDX, Scientific Laboratories Alliance, ELAJ, Genetrack Saudi Arabia, OncoDNA and More
06 nov. 2024 05h05 HE
|
Research and Markets
Dublin, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The "Saudi Arabia Genetic Testing Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
04 nov. 2024 08h39 HE
|
Myriad Genetics, Inc.
Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
30 oct. 2024 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its third quarter earnings conference call on Thursday, Nov. 7, 2024 at 4:30 pm ET.